Daré Bioscience (DARE) Q3 2025 Earnings Transcript

Daré Bioscience (DARE) reported Phase 1 data for its Sildenafil Cream, showing lower systemic exposure than oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and found significantly lower plasma concentrations for topical administration. The cream is being developed for women's sexual health. DARE stock is currently trading at $0.71, up 0.69%.

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances Company launches Flora Sync LF5™, the company’s first directly commercialized product, began generating revenue in July DARE to

Daré Bioscience (NASDAQ: DARE) said its vaginal probiotic Flora Sync LF5 is now available for order via its DARE Health Hub, marking the company’s first direct-to-consumer product revenue. The product is priced at $49 per box (6 capsules, 2 courses) and is non-prescription. Daré also cited ongoing Phase 2 DARE-HPV and Phase 3 Ovaprene progress.

Novo Nordisk (NYSE: NVO) plans to diversify beyond obesity and diabetes, aiming for over DKK 150 billion in pipeline sales by 2035. The company faces competition and pricing pressure, with obesity and diabetes accounting for 90% of 2025 sales. Novo is expanding its portfolio and may pursue acquisitions, but risks include high costs and execution challenges.

Bank of America downgraded Nike to Underperform, cutting its price target to $30 from $47. Analyst Lorraine Hutchinson delayed sales recovery expectations to fiscal 2028, reducing EPS estimates. China revenue fell 17% in Q4, and wholesale partners face inventory issues. Nike shares have dropped over 40% since January, nearing 52-week lows.

Berenberg initiated coverage of AST SpaceMobile (ASTS) with a Buy rating and a $92 price target, citing its space-based cellular broadband positioning and mobile operator partnerships. The article also notes BlueBird satellite launch progress, expectations for ~45 satellites by early 2027, and ASTS Q2 2026 revenue of $31.5M.